AB010. A phase 1 trial of PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), alone or in combination with pembrolizumab, for the treatment of thymic malignancies

ABSTRACT:

SUBMITTER: Meric-Bernstam F 

PROVIDER: S-EPMC12529548 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature